Advertisement

Critical Acute Akinesia in Parkinson’s Disease Patients Concomitant with Additional Precipitating Factors Other Than Treatment Withdrawal: A Possible Lethal Complication

  • Marco Onofrj
  • Astrid Thomas
Conference paper
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)

Keywords

Neuroleptic Malignant Syndrome Lewy Body Dementia Unify Parkinson Disease Rate Scale Parkinsonian Motor Symptom Amantadine Sulfate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology 2005;64:1162–1169.PubMedGoogle Scholar
  2. 2.
    Kipps CM, Fung VSC, Grattan-Smith P, de Moore GM, Morris JGL. Movement disorders emergencies. Mov Disord doi: 10.1002/mds.20325.Google Scholar
  3. 3.
    Friedman JH, Feinberg SS, Feldman RC. Neuroleptic malignant-like syndrome due to l-dopa withdrawal. Ann Neurol 1984;16:126.Google Scholar
  4. 4.
    Granner MA, Wooten GF. Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome. Semin Neurol 1991;11:228–235.PubMedCrossRefGoogle Scholar
  5. 5.
    Takubo H, Harada T, Hashimoto T, et al, A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 2003;9:S31–S41.PubMedCrossRefGoogle Scholar
  6. 6.
    Quinn NP. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998;51(Suppl 2):S25–S29.PubMedGoogle Scholar
  7. 7.
    Stacy M, Factor S. Rapid treatment of “off” episodes: will this change Parkinson disease therapy? Neurology 2004;62(Suppl 4):S1–S2.Google Scholar
  8. 8.
    Danielczyk W. Die Behandlung von akinetischen Krisen. Med Welt 1973;24:1278–1282.PubMedGoogle Scholar
  9. 9.
    Muschard G, Völler GW. Wirksamkeit von Amantadinsulfat als Infusionslösung bei der Behandlung des Parkinsons Sindroms. Med Welt 1973;24:183–184.PubMedGoogle Scholar
  10. 10.
    Oppel F, Klaes H. Die Amantadin-Infusionen in der akuten Behandlung der Morbus Parkinson. Klinikarzt 1981;10:559–565.Google Scholar
  11. 11.
    Deutsche Gesellschaft fúr Neurologie: Leitlinien-Parkinson-Syndrome; 4,3,4,2 Akinetische Krise. http://www.dgn.org/168.0htlm#926.
  12. 12.
    Tanner CM, Goetz CG, Klawans HL. Autonomic nervous system disorders. In: Koller WC (ed) Handbook of Parkinson's Disease. Marcel Dekker, New York, 1987, pp 161–163.Google Scholar
  13. 13.
    Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's disease. J Neural Transm Suppl 1995;46:399–409.PubMedGoogle Scholar
  14. 14.
    Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989;50:18–25.PubMedGoogle Scholar
  15. 15.
    McKeith I, Misumann U. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord 2004;10(Suppl 1):S15–S18.PubMedCrossRefGoogle Scholar
  16. 16.
    Dickson DW. Neuropathology of Parkinsonian disorders. In: Jankovic J, Tolosa E (eds) Parkinson's Disease and Movement Disorders, 4th ed. Lippincott Williams & Wilkins, Philadelphia, 2002, pp 256–269.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Marco Onofrj
    • 1
  • Astrid Thomas
  1. 1.Neurophysiopathology, Movement Disorders Center, Department of Oncology and NeuroscienceUniversity “G.D’ Annunzio” Chieti-Pescara, and Aging Research Center, Ce.S.I., “Gabriele D’ Annunzio” University FoundationChieti-PescaraItaly

Personalised recommendations